PLoS By Category | Recent PLoS Articles

Critical Care and Emergency Medicine - Hematology - Pharmacology

Clinical Presentations, Antiplatelet Strategies and Prognosis of Patients with Stent Thrombosis: An Observational Study of 140 Patients
Published: Wednesday, October 31, 2012
Author: Ya-Ling Han et al.

by Ya-Ling Han, Quan-Yu Zhang, Yi Li, Shao-Yi Guan, Quan-Min Jing, Zu-Lu Wang, Xin Zhao, Xiao-Zeng Wang, Ying-Yan Ma, Bin Wang, Jie Deng, Geng Wang, Young-Hak Kim


Until now there has been scarce evidence regarding an optimal antiplatelet strategy and clinical outcomes for patients who had suffered from stent thrombosis (ST).

Methods and Results

140 patients who suffered from stent thrombosis were prospectively registered. Patients received dual (aspirin and 150 mg clopidogrel, N?=?66) or triple (additional cilostazol, N?=?74) antiplatelet therapy at the physician’s discretion. Thereafter platelet reactivity and one year clinical outcomes were analyzed. The primary outcome included the composite of cardiac death, non-fatal myocardial infarction (MI) or stroke at one year,which developed in 41 (29.3%) patients, consisting of 31 (22.1%) cardiac death, 9 (6.4%) non-fatal MI and 1 (1.4%) stroke. Recurrent definite and probable ST according to ARC definition was observed in 8 (5.7%) and 14 (10.0%) patients, respectively. Triple therapy was associated with significantly lower platelet reactivities (50.2±17.8, % vs. 59.6±17.2, %, P?=?0.002) compared to high dose dual antiplatelet therapy. However, the incidence of primary events (24.3% vs. 34.8%, P?=?0.172) did not differ between triple and dual antiplatelet therapies. High on-treatment platelet reactivity (HR: 8.35, 95% CI: 2.234~30.867, P?=?0.002) and diabetes (HR: 3.732, 95% CI: 1.353~10.298, P?=?0.011) were independent predictors of primary events.


Patients who suffered from stent thrombosis have a poor prognosis even after revascularization with intensive antiplatelet therapy. Triple antiplatelet therapy was more effective in reducing on-treatment platelet reactivity, compared to high dose dual antiplatelet therapy.